Trial Profile
A proof-of-concept clinical trial of a lead non-bile acid FXR agonist in patients with non-alcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Farnesoid X-activated receptor agonists (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept
- 13 Apr 2016 New trial record